9/19/2013

The FDA has granted Profound Medical investigational device exemption approval to conduct a clinical study of its device that uses real-time MRI guidance and thermal ultrasound to treat patients with localized prostate cancer. The Canadian company plans to start patient enrollment in the trial in late 2013.

Related Summaries